Peptide receptor radiotherapy with somatostatin analogs has been successfully used for
years as a treatment for somatostatin-overexpressing tumors. Treatment of neuroendocrine …

Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel
treatment modality that delivers highly potent alpha-particles to cancer cells or their …

This article highlights recent developments of SPECT and PET diagnostic imaging
surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the …

The approval of 223 RaCl 2 for cancer therapy in 2013 has heralded a resurgence of
interest in the development of α-particle emitting radiopharmaceuticals. In the last decade …

203Pb and 212Pb have emerged as promising theranostic isotopes for image-guided α-
particle radionuclide therapy for cancers. Here, we report a cyclen-based Pb specific …

Abstract Introduction 203 Pb (t 1/2= 51.9 h, 279 keV (81%)) is a diagnostic SPECT imaging
radionuclide ideally suited for theranostic applications in combination with 212 Pb for …

Bone metastases are a painful and complex condition that overwhelmingly impacts the
prognosis and quality of life of cancer patients. Over the years, nuclear medicine has made …

The development of diagnostic methods in medicine as well as the progress in the synthesis
of biologically active compounds allows the use of selected radioisotopes for the …

In vivo alpha particle generators have great potential for the treatment of neuroendocrine
tumors in alpha-emitter-based peptide receptor radionuclide therapy (α-PRRT). Quantitative …

212Pb is a promising radionuclide for targeted alpha particle therapy for cancer. Ongoing
preclinical and clinical studies are investigating the potential of 212Pb-labeled peptides and …